MedKoo Cat#: 563743 | Name: NSC-57969
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC-57969 is a MDR-selective agent, exhibiting a robust Pgp-dependent toxic activity across diverse cancer cell lines.

Chemical Structure

NSC-57969
NSC-57969
CAS#6632-09-3

Theoretical Analysis

MedKoo Cat#: 563743

Name: NSC-57969

CAS#: 6632-09-3

Chemical Formula: C15H18N2O

Exact Mass: 242.1419

Molecular Weight: 242.32

Elemental Analysis: C, 74.35; H, 7.49; N, 11.56; O, 6.60

Price and Availability

Size Price Availability Quantity
5mg USD 260.00
25mg USD 610.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NSC-57969; NSC 57969; NSC57969;
IUPAC/Chemical Name
7-(1-Piperidinylmethyl)-8-quinolinol
InChi Key
WXMFPLZGDXLEMN-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H18N2O/c18-15-13(11-17-9-2-1-3-10-17)7-6-12-5-4-8-16-14(12)15/h4-8,18H,1-3,9-11H2
SMILES Code
OC1=C2N=CC=CC2=CC=C1CN3CCCCC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Biological target:
NSC-57969 is a MDR-selective agent.
In vitro activity:
Pgp expression associated with the resistance of the doxorubicin-resistant Brca1-/-;p53-/- spontaneous mouse mammary carcinoma cells could be eliminated by a single treatment with NSC57969, suggesting that MDR-selective compounds can effectively revert the MDR phenotype of cells expressing Pgp at clinically relevant levels. Reference: Mol Cancer Ther. 2017 Jan;16(1):45-56. https://pubmed.ncbi.nlm.nih.gov/27760838/
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 242.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Füredi A, Tóth S, Szebényi K, Pape VF, Türk D, Kucsma N, Cervenak L, Tóvári J, Szakács G. Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity. Mol Cancer Ther. 2017 Jan;16(1):45-56. doi: 10.1158/1535-7163.MCT-16-0333-T. Epub 2016 Oct 19. PMID: 27760838.
In vitro protocol:
Füredi A, Tóth S, Szebényi K, Pape VF, Türk D, Kucsma N, Cervenak L, Tóvári J, Szakács G. Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity. Mol Cancer Ther. 2017 Jan;16(1):45-56. doi: 10.1158/1535-7163.MCT-16-0333-T. Epub 2016 Oct 19. PMID: 27760838.
In vivo protocol:
TBD
1: Füredi A, Tóth S, Szebényi K, Pape VF, Türk D, Kucsma N, Cervenak L, Tóvári J, Szakács G. Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity. Mol Cancer Ther. 2017 Jan;16(1):45-56. doi: 10.1158/1535-7163.MCT-16-0333-T. Epub 2016 Oct 19. PubMed PMID: 27760838.